©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 89-93, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/1228993 IDOSRJES12206

Polymeric Nanoparticle Drug Delivery Systems Enhancing Lumefantrine Bioavailability in Uncomplicated Malaria Treatment

Waiswa Arajab

Department of Pharmacy Kampala International University Uganda
Email: arajab.waiswa@studwc.kiu.ac.ug

ABSTRACT

Malaria remained a major global health challenge, with uncomplicated malaria accounting for most clinical cases in endemic regions. Artemisinin-based combination therapy remained the cornerstone of treatment, and lumefantrine played a crucial role as the long-acting partner drug in artemether-lumefantrine therapy. However, lumefantrine exhibits poor aqueous solubility, erratic intestinal absorption, and strong dependence on dietary lipids, resulting in highly variable bioavailability and suboptimal therapeutic exposure in some patients. The purpose of this review was to examine the role of polymeric nanoparticle drug delivery systems in enhancing lumefantrine bioavailability and improving therapeutic outcomes in uncomplicated malaria. A structured narrative review methodology was used to synthesize findings from peer-reviewed literature on lumefantrine pharmacokinetics and polymeric nanoparticle-based drug delivery. Evidence indicated that polymeric nanoparticles improved lumefantrine solubility, protected the drug from premature metabolism, enhanced intestinal permeability, and sustained plasma drug concentrations, thereby improving antimalarial efficacy in experimental models. These systems also reduced dependence on dietary fat and provided more predictable pharmacokinetic profiles. Polymeric nanoparticle formulations therefore represented a promising strategy for optimizing lumefantrine therapy and improving malaria treatment outcomes. Further clinical evaluation and scalable manufacturing approaches were recommended to support translation into routine malaria treatment.

Keywords: Lumefantrine, Polymeric nanoparticles, Bioavailability, Malaria treatment, Drug delivery

INTRODUCTION

Malaria remains one of the most significant infectious diseases worldwide, particularly in tropical and subtropical regions where transmission is sustained by favorable climatic and ecological conditions [1, 2]. Uncomplicated malaria accounts for the majority of diagnosed cases and is primarily caused by *Plasmodium falciparum* and *Plasmodium vivax* [3]. Artemisinin-based combination therapy represents the recommended first-line treatment, with artemether-lumefantrine being among the most widely used regimens. Lumefantrine serves as the long-acting partner drug responsible for eliminating residual parasites after rapid parasite clearance by artemether [4]. Despite its therapeutic importance, the clinical effectiveness of lumefantrine is limited by unfavorable physicochemical and pharmacokinetic characteristics that reduce systemic drug exposure.

Lumefantrine is highly lipophilic and exhibits extremely low aqueous solubility, leading to slow dissolution within the gastrointestinal tract [5]. Its absorption is strongly dependent on the presence of dietary fat, which increases solubilization and enhances intestinal uptake. In many malaria endemic regions, inconsistent food intake results in variable lumefantrine plasma concentrations, increasing the risk of treatment failure and the emergence of drug-resistant parasite strains [6, 7]. Conventional formulations therefore do not always achieve optimal therapeutic concentrations.

Polymeric nanoparticle drug delivery systems have emerged as promising tools for improving the pharmacological performance of poorly soluble drugs [8]. These systems can enhance dissolution rates, increase intestinal permeability, and provide sustained drug release. This review discusses the biopharmaceutical limitations of lumefantrine, the principles of polymeric nanoparticle drug delivery, the mechanisms by which nanoparticles enhance lumefantrine bioavailability, experimental evidence supporting their use, and the clinical and translational implications of these technologies. The purpose of this study is to evaluate polymeric nanoparticle drug delivery systems as a strategy for improving lumefantrine bioavailability and therapeutic effectiveness in uncomplicated malaria treatment.

Biopharmaceutical and Pharmacokinetic Limitations of Lumefantrine

Lumefantrine is a highly lipophilic antimalarial compound with a molecular structure dominated by aromatic rings and hydrophobic substituents that confer extremely low aqueous solubility [5, 9]. The drug is generally categorized as a Biopharmaceutics Classification System class II compound, characterized by low solubility and high permeability. For such compounds, dissolution becomes the primary factor limiting systemic drug absorption.

Following oral administration, lumefantrine dissolves slowly in gastrointestinal fluids, resulting in delayed and incomplete absorption [10]. The presence of dietary lipids enhances solubilization through micelle formation, which significantly increases drug uptake. Clinical studies have demonstrated that lumefantrine plasma concentrations may increase severalfold when doses are administered with fatty meals. However, patients in malaria endemic settings often have reduced appetite or limited access to lipid-rich foods, producing substantial variability in drug exposure.

Lumefantrine undergoes hepatic metabolism primarily through cytochrome P450 enzymes, particularly CYP3A4, producing the active metabolite desbutyl lumefantrine [11]. Extensive first-pass metabolism may reduce the amount of parent drug reaching systemic circulation. Variability in enzyme activity further contributes to inconsistent pharmacokinetic profiles.

Subtherapeutic lumefantrine concentrations are associated with incomplete parasite clearance and increased risk of recrudescence [12]. Low drug exposure also promotes selection of resistant parasite populations. These limitations highlight the need for improved delivery systems capable of enhancing dissolution and stabilizing plasma drug concentrations. Polymeric nanoparticle formulations offer a promising approach to overcoming these constraints by modifying drug release and absorption characteristics at the molecular and cellular levels.

Polymeric Nanoparticle Drug Delivery Systems: Principles and Mechanistic Basis

Polymeric nanoparticles are colloidal drug delivery systems typically ranging from 10 to 1000 nanometers in diameter and composed of biodegradable or biocompatible polymers [13]. These systems can be engineered to encapsulate hydrophobic drugs within polymer matrices or adsorb drug molecules onto particle surfaces. Commonly used polymers include chitosan, polycaprolactone, and polyethylene glycol-modified copolymers.

Drug encapsulation within polymer matrices improves dispersion of poorly soluble compounds in aqueous environments [14]. The nanoscale dimensions of these particles greatly increase surface area relative to volume, enhancing interaction with gastrointestinal fluids and accelerating dissolution processes. Controlled release properties can be achieved by modifying polymer composition, molecular weight, and particle architecture. Surface modification strategies allow nanoparticles to interact more efficiently with biological membranes. Hydrophilic polymer coatings such as polyethylene glycol improve particle stability and reduce aggregation in biological fluids [15]. Positively charged polymers such as chitosan can enhance adhesion to intestinal mucosa, prolonging residence time and facilitating drug absorption.

Polymeric nanoparticles can also influence drug transport across epithelial barriers [16, 17]. Nanoparticles may be internalized through endocytosis or facilitate diffusion of released drug molecules across cellular membranes. These processes increase the fraction of administered drug reaching systemic circulation [18]. The biodegradability of commonly used polymers ensures gradual breakdown into non-toxic metabolites. This characteristic makes polymeric nanoparticles particularly suitable for oral drug delivery in chronic and infectious diseases. Their ability to modify pharmacokinetic profiles provides a mechanistic basis for improving lumefantrine bioavailability.

Mechanisms by Which Polymeric Nanoparticles Enhance Lumefantrine Bioavailability

Polymeric nanoparticles improve lumefantrine bioavailability through multiple complementary mechanisms. One of the most important effects is enhancement of aqueous dispersion. Encapsulation within polymer matrices allows lumefantrine to be distributed uniformly in nanoscale particles, preventing aggregation and increasing effective surface area available for dissolution [19]. This leads to faster drug release into gastrointestinal fluids compared with conventional crystalline formulations. Nanoparticle formulations also protect lumefantrine from premature degradation and metabolism. The polymer matrix acts as a diffusion barrier that slows exposure of the drug to intestinal enzymes and hepatic metabolism. Sustained release properties maintain therapeutic concentrations over extended periods, reducing fluctuations in plasma drug levels.

Enhanced intestinal permeability represents another important mechanism. Nanoparticles interact closely with intestinal epithelial cells, increasing the local concentration gradient that drives passive diffusion [20]. Some polymer systems transiently modify tight junction integrity or promote endocytic uptake, facilitating transcellular

transport of encapsulated drug molecules. Polymeric nanoparticles may reduce the dependence of lumefantrine absorption on dietary lipids. Because the drug is already dispersed in nanoscale particles, solubilization does not rely solely on bile salt micelles. This property can produce more consistent absorption under fasting conditions.

Efflux transporters such as P-glycoprotein may limit lumefantrine absorption by transporting drug molecules back into the intestinal lumen [21]. Certain polymeric systems reduce transporter-mediated efflux by altering intracellular drug trafficking pathways. Collectively, these mechanisms lead to increased systemic exposure and improved therapeutic efficacy.

Preclinical and Translational Evidence Supporting Nanoparticle-Based Lumefantrine Delivery

Preclinical investigations have demonstrated significant improvements in lumefantrine dissolution and bioavailability when polymeric nanoparticle formulations are used [22]. In vitro release studies consistently show faster and more complete dissolution compared with conventional tablet formulations. Nanoparticle systems prepared with biodegradable polymers exhibit controlled release patterns that maintain therapeutic concentrations over extended periods.

Animal pharmacokinetic studies provide strong evidence for enhanced systemic exposure. Nanoparticle formulations typically produce higher peak plasma concentrations and greater area under the concentration-time curve than conventional formulations. Sustained drug release leads to prolonged elimination phases and improved maintenance of therapeutic concentrations. Experimental malaria models have shown improved parasite clearance when lumefantrine is delivered in nanoparticle form. Reduced parasitemia and prolonged suppression of parasite growth have been observed in treated animals. These outcomes are consistent with improved drug exposure and sustained plasma concentrations.

Toxicological evaluations generally indicate favorable safety profiles for polymeric nanoparticles composed of biodegradable materials [23, 24]. Minimal organ toxicity and acceptable tolerability have been reported in short term studies. However, long term safety data remain limited. Despite encouraging results, translation into clinical practice requires additional investigation. Human pharmacokinetic studies and controlled clinical trials are necessary to confirm improvements observed in experimental systems. Standardization of formulation methods will be essential for reproducible performance.

Clinical Implications, Regulatory Considerations, and Future Research Directions

Polymeric nanoparticle formulations of lumefantrine have important potential implications for malaria treatment in endemic regions. Improved bioavailability may enhance cure rates of lumefantrine and reduce the frequency of treatment failure [25]. More predictable pharmacokinetic profiles could decrease the emergence of resistant parasite strains by maintaining therapeutic drug concentrations throughout the treatment period. Nanoparticle formulations may be particularly valuable in pediatric and malnourished populations where dietary fat intake is inconsistent. Reduced dependence on food intake would improve treatment reliability in resource-limited settings.

Manufacturing scalability remains a major consideration for widespread implementation. Production methods must be cost-effective and capable of generating stable formulations under tropical storage conditions. Stability during transport and long-term storage is essential for deployment in endemic regions.

Regulatory approval of lumefantrine will require demonstration of safety, quality, and therapeutic equivalence or superiority compared with existing formulations [26]. Standardized evaluation methods are needed to ensure consistency across production batches. Future research should focus on optimization of polymer composition, particle size distribution, and release kinetics to maximize therapeutic benefit. Integration with existing artemisinin-based combination therapy regimens will be essential for clinical adoption.

CONCLUSION

Lumefantrine remains an essential component of artemisinin-based combination therapy for uncomplicated malaria, yet its therapeutic effectiveness is limited by poor aqueous solubility and variable oral absorption. Dependence on dietary fat and extensive first-pass metabolism contribute to inconsistent systemic exposure, which may compromise treatment outcomes and promote the development of drug resistance. Polymeric nanoparticle drug delivery systems provide a rational and mechanistically sound approach to overcoming these limitations by enhancing drug dispersion, improving dissolution rates, increasing intestinal permeability, and sustaining plasma drug concentrations. Experimental evidence demonstrates that polymeric nanoparticle formulations significantly improve lumefantrine pharmacokinetic profiles and antimalarial efficacy in preclinical models. These systems offer the additional advantage of reducing variability associated with food-dependent absorption, making them particularly relevant for malaria-endemic regions. Advances in biodegradable polymer technology and nanoscale drug engineering continue to improve the feasibility of these delivery platforms. Well-designed clinical trials and scalable manufacturing strategies are required before polymeric nanoparticle lumefantrine formulations can be integrated into routine malaria treatment. Polymeric nanoparticle formulations of lumefantrine should be prioritized for clinical development as a strategy to improve therapeutic reliability in uncomplicated malaria.

REFERENCES

1. Kogan, F.: Malaria Burden. In: Kogan, F. (ed.) Remote Sensing for Malaria: Monitoring and Predicting Malaria from Operational Satellites. pp. 15–41. Springer International Publishing, Cham (2020)
2. Alum, E.U., Ugwu, O.P.-C., Egba, S.I., Uti, D.E., Alum, B.N.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR SR. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Tsamesidis, I., M Aja, P., E Offor, C., Ajuka Obasi, N.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr H. Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
4. Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine (Baltimore). 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
5. Tay, E., Nguyen, T.-H., Ford, L., Williams, H.D., Benameur, H., Scammells, P.J., Porter, C.J.H.: Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. Pharmaceutics. 12, (2019). https://doi.org/10.3390/pharmaceutics12010017
6. Barman, K., Goswami, P.: Recent Advances in Diagnostics and Therapeutic Interventions for Drug-Resistant Malaria. ACS Infect. Dis. 11, 1296–1332 (2025). https://doi.org/10.1021/acsinfecdis.4c00962
7. Thomford, N.E., Kellermann, T., Biney, R.P., Dixon, C., Nyarko, S.B., Ateko, R.O., Ekor, M., Kyei, G.B.: Therapeutic efficacy of generic artemether–lumefantrine in the treatment of uncomplicated malaria in Ghana: assessing anti-malarial efficacy amidst pharmacogenetic variations. Malar J. 23, 125 (2024). https://doi.org/10.1186/s12936-024-04930-1
8. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
9. Khan, S., Baboota, S., Ali, J., Khan, S., Narang, R.S., Narang, J.K.: Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 5, 182–191 (2015). https://doi.org/10.4103/2230-973X.167661
10. du Plessis, L.H., Govender, K., Denti, P., Wiesner, L.: *In vivo* efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. European Journal of Pharmaceutics and Biopharmaceutics. 97, 68–77 (2015). https://doi.org/10.1016/j.ejpb.2015.10.001
11. Zhang, X., Li, Q., Zhou, Q., Li, Y., Li, J., Jin, L., Li, S., Cai, J., Chen, G., Hu, G., Qian, J.: Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine. Food and Chemical Toxicology. 181, 114065 (2023). https://doi.org/10.1016/j.fct.2023.114065
12. Schnyder, J.L., Bache, B.E., Hoogakker, M., Van De Ruit, M., Zonneveld, R., Hermans, S.M., Stijnis, C., Van Vugt, M., Hänscheid, T., Van Hest, R.M., Goorhuis, A., de Jong, H.K., Grobusch, M.P.: Malaria recrudescence after artemether-lumefantrine treatment in travellers– a hospital-based observational study and literature review. Trop Dis Travel Med Vaccines. 11, 19 (2025). https://doi.org/10.1186/s40794-025-00256-1
13. Ram Prasad, R.P., Rishikesh Pandey, R.P., Ajit Varma, A.V., Ishan Barman, I.B.: Polymer-based nanoparticles for drug delivery systems and cancer therapeutics. In: Harsha Kharkwal, H.K. and Srinivas Janaswamy, S.J. (eds.) Natural polymers for drug delivery. pp. 53–70. CABI, UK (2017)
14. Tran, T.T.D., Tran, P.H.L.: Nanoconjugation and Encapsulation Strategies for Improving Drug Delivery and Therapeutic Efficacy of Poorly Water-Soluble Drugs. Pharmaceutics. 11, (2019). https://doi.org/10.3390/pharmaceutics11070325
15. Long, H.P., Lai, C.C., Chung, C.K.: Polyethylene glycol coating for hydrophilicity enhancement of polydimethylsiloxane self-driven microfluidic chip. Surface and Coatings Technology. 320, 315–319 (2017). https://doi.org/10.1016/j.surfcoat.2016.12.059
16. Ejazi, S.A., Louisthelmy, R., Maisel, K.: Mechanisms of Nanoparticle Transport across Intestinal Tissue: An Oral Delivery Perspective. ACS Nano. 17, 13044–13061 (2023). https://doi.org/10.1021/acsnano.3c02403
17. Liu, Y., Jiang, Z., Hou, X., Xie, X., Shi, J., Shen, J., He, Y., Wang, Z., Feng, N.: Functional lipid polymeric nanoparticles for oral drug delivery: Rapid mucus penetration and improved cell entry and cellular transport. Nanomedicine: Nanotechnology, Biology and Medicine. 21, 102075 (2019). https://doi.org/10.1016/j.nano.2019.102075
18. Nwuruku, O.A., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
19. Shevalkar, G., Pawar, M., Vavia, P.: Nanostructured Lipid Carriers (NLCs) of Lumefantrine with Enhanced Permeation. J Pharm Innov. 17, 1221–1234 (2022). https://doi.org/10.1007/s12247-021-09590-1
20. Ejazi, S.A., Louisthelmy, R., Maisel, K.: Mechanisms of Nanoparticle Transport across Intestinal Tissue: An Oral Delivery Perspective. ACS Nano. 17, 13044–13061 (2023). https://doi.org/10.1021/acsnano.3c02403

21. Nguyen, T.-T.-L., Duong, V.-A., Maeng, H.-J.: Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics. 13, (2021). https://doi.org/10.3390/pharmaceutics13071103
22. du Plessis, L.H., Govender, K., Denti, P., Wiesner, L.: *In vivo* efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. European Journal of Pharmaceutics and Biopharmaceutics. 97, 68–77 (2015). https://doi.org/10.1016/j.ejpb.2015.10.001
23. Sadaquat, H., Akhtar, M., Nazir, M., Ahmad, R., Alvi, Z., Akhtar, N.: Biodegradable and biocompatible polymeric nanoparticles for enhanced solubility and safe oral delivery of docetaxel: *In vivo* toxicity evaluation. International Journal of Pharmaceutics. 598, 120363 (2021). https://doi.org/10.1016/j.ijpharm.2021.120363
24. Patel, P., Vyas, N., Raval, M.: Safety and Toxicity issues of Polymeric Nanoparticles. In: Nanotechnology in Medicine. pp. 156–173. John Wiley & Sons, Ltd (2021)
25. du Plessis, L.H., Govender, K., Denti, P., Wiesner, L.: *In vivo* efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. European Journal of Pharmaceutics and Biopharmaceutics. 97, 68–77 (2015). https://doi.org/10.1016/j.ejpb.2015.10.001
26. Nyarko, S., Ofori-Kwakye, K., Johnson, R., Kuntworbe, N., Yar, D.D.: Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana. Advances in Pharmacological and Pharmaceutical Sciences. 2024, 2650540 (2024). https://doi.org/10.1155/2024/2650540

CITE AS: Waiswa Arajab (2026). Polymeric Nanoparticle Drug Delivery Systems Enhancing Lumefantrine Bioavailability in Uncomplicated Malaria Treatment. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 89-93. https://doi.org/10.59298/IDOSR/JES/06/1228993